Multidrug-resistant tuberculosis
| dc.creator | Urrego-Díaz, Jose Augusto | |
| dc.date | 2020-07-22 | |
| dc.date.accessioned | 2025-08-22T21:28:43Z | |
| dc.date.available | 2025-08-22T21:28:43Z | |
| dc.description | Tuberculosis (TB) is the worldwide leading infectious cause of death and, the emergence of drug-resistant tuberculosis can only worsen the scenario. Multidrug-Resistant Tuberculosis (TB-MDR) has proven resistant to both isoniazid and rifampin, the main antituberculous drugs. Out of 10 million people developing TB annually, 458 000 exhibit TB-MDR, having worse prognosis than those infected by sensitive strains. Recently, new drug-resistant TB treatment guidelines were issued both by the World Health Organization and health authorities in Colombia. The present paper explores the main aspects of TB-MDR emphasizing s sanitary authorities also, new guidelines were published by Colombian minister of health and social protection. In this paper, the main aspects of TB-MDR are explored, especially those related to its treatment. | en-US |
| dc.description | La tuberculosis (TB) es la enfermedad bacteriana infecciosa que más muertes causa en el mundo, panorama que puede empeorar debido a la drogorresistencia. La tuberculosis multidrogoresistente (TB-MDR), es decir la que presenta resistencia simultánea a isoniazida y rifampicina (principales fármacos antituberculosos), tiene una relevancia particular: de los 10 millones de personas que desarrollan TB anualmente, 458.000 presentan TB-MDR con un pronóstico mucho peor que el de los infectados por cepas sensibles. En el presente artículo se exploran los principales aspectos de la TB-MDR, haciendo énfasis en su tratamiento. | es-ES |
| dc.format | application/pdf | |
| dc.format | application/xml | |
| dc.format | text/html | |
| dc.format | application/epub+zip | |
| dc.identifier | https://revistas.unbosque.edu.co/index.php/RSB/article/view/2834 | |
| dc.identifier | 10.18270/rsb.v10i1.2834 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12495/17540 | |
| dc.language | spa | |
| dc.publisher | Universidad El Bosque | es-ES |
| dc.relation | https://revistas.unbosque.edu.co/index.php/RSB/article/view/2834/2414 | |
| dc.relation | https://revistas.unbosque.edu.co/index.php/RSB/article/view/2834/2381 | |
| dc.relation | https://revistas.unbosque.edu.co/index.php/RSB/article/view/2834/2380 | |
| dc.relation | https://revistas.unbosque.edu.co/index.php/RSB/article/view/2834/2415 | |
| dc.source | Revista Salud Bosque; Vol. 10 No. 1 (2020): Salud Bosque | en-US |
| dc.source | Revista Salud Bosque; Vol. 10 Núm. 1 (2020): Salud Bosque | es-ES |
| dc.source | 2322-9462 | |
| dc.source | 2248-5759 | |
| dc.subject | Tuberculosis | en-US |
| dc.subject | Infection | en-US |
| dc.subject | Multidrug-Resistant | en-US |
| dc.subject | Treatment | en-US |
| dc.subject | Antitubercular agents | en-US |
| dc.subject | Tuberculosis | es-ES |
| dc.subject | Infección | es-ES |
| dc.subject | Farmacorresistencia Microbiana | es-ES |
| dc.subject | Quimioterapia | es-ES |
| dc.subject | Agentes Antituberculosos | es-ES |
| dc.title | Multidrug-resistant tuberculosis | en-US |
| dc.title | Tuberculosis multidrogorresistente | es-ES |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:eu-repo/semantics/publishedVersion |